BRD4 and ovarian carcinoma: The analysis of the mRNA-Seq data of ovarian cancer patients (all grades) from the kmplot database (www.kmplot.com (accessed on 15 November 2020)) revealed that the overexpression of BRD4 in ovarian cancer patients led to significantly reduced OS compared to low BRD4 expressing patients (36.8 vs. 48.4 months) (Figure 3f, left panel).